Intech Investment Management LLC Invests $68,000 in Inozyme Pharma, Inc. (NASDAQ:INZY)

Intech Investment Management LLC bought a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 24,587 shares of the company’s stock, valued at approximately $68,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at $38,000. Palumbo Wealth Management LLC lifted its position in Inozyme Pharma by 52.3% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock valued at $64,000 after purchasing an additional 7,995 shares in the last quarter. Virtu Financial LLC purchased a new stake in Inozyme Pharma in the third quarter worth about $64,000. Readystate Asset Management LP bought a new position in shares of Inozyme Pharma in the third quarter worth about $100,000. Finally, JPMorgan Chase & Co. lifted its holdings in Inozyme Pharma by 31.0% during the third quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock valued at $151,000 after purchasing an additional 6,851 shares in the last quarter. 88.30% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Inozyme Pharma in a research note on Tuesday, March 11th. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price (down from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Raymond James reduced their price target on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, March 12th. Wells Fargo & Company dropped their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Finally, Needham & Company LLC reduced their target price on Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Inozyme Pharma currently has a consensus rating of “Buy” and an average price target of $14.56.

Inozyme Pharma Trading Down 7.5 %

INZY opened at $0.92 on Friday. The stock has a 50-day moving average of $1.22 and a 200 day moving average of $2.93. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma, Inc. has a 12 month low of $0.91 and a 12 month high of $7.80. The firm has a market cap of $59.10 million, a P/E ratio of -0.59 and a beta of 1.32.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.